Financial Performance
5Y price score: (84)
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 753.9%
US$ Per
Share
By default your notes are visible only to you.
22.2
52-week range
176.6
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
(2) %
Dividend Yield TTM
-
Market cap $
$ 63,022
Price / Earnings TTM
(19.9)
Price / Book TTM
9.3
PEG TTM
(2.5)
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
526.5 %
(60.1) %
753.9 %
Free cash flow per share growth
40.2 %
(203.3) %
-
Earnings per share growth
8 %
(270.4) %
-
Founded: 2,010
Employees: 5,800
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Jul 31, 2026)
1) Financial Overview and Performance - Revenue for Q2 2026 was $145 million, exceeding guidance and up 2% YoY. - Total revenue for the first half of 2026 reached $0.5 billion, with 31% from the U.S. and 69% from international markets. - The company reported a net loss of $782 million, an improvement of $43 million from the previous year. - Cash and investments at the end of Q2 stood at $6.9 billion, down from $7.5 billion at the end of Q1 2026. - Guidance for 2026 remains at up to 10% revenue growth, with expectations of a 50-50 split between U.S. and international revenue.
2) Pipeline and Product Updates - The seasonal flu vaccine, mRNA-1010, received a positive recommendation from the U.S. VRBPAC, with a PDUFA date set for August 5, 2026. - The norovirus vaccine (mRNA-1403) is preparing to enroll an additional cohort in its Phase III trial after an interim analysis. - In oncology, the Intismeran program continues to show promise, with a 5-year update presented at ASCO 2026. - Dosing has begun in two new cancer antigen therapy programs: mRNA-4194 in Lynch syndrome and mRNA-4200 in solid tumors.
3) Strategic Leadership Changes - Ester Banque has been appointed as the new Chief Commercial Officer, bringing over 30 years of experience in commercial leadership. - Michael McDonnell has joined Moderna's Board of Directors, enhancing the board's expertise in finance and corporate governance.
4) Operational Efficiency and Cost Management - Cash costs were reduced by 10% compared to Q2 2025. - Cost of sales decreased by 22% YoY to $93 million, attributed to improved manufacturing efficiency. - R&D expenses were down 7% YoY to $651 million, reflecting operational efficiencies.
5) Challenges and Future Outlook - The company faces potential declines in COVID vaccination rates, impacting revenue projections. - The Phase III trial for Intismeran in melanoma is ongoing, with interim analysis expected in the second half of 2026. - The transcript lacks specific details on the timing of certain clinical trial readouts and the broader implications of interim results.
Bottom line: Moderna is positioned for growth with a strong pipeline and strategic leadership changes, but faces challenges from declining COVID vaccination rates and ongoing clinical trials. The focus on operational efficiency and cost management is crucial as the company navigates these headwinds while aiming for revenue growth in 2026.
Annual Reports, Presentations And IR Contacts
Go to the websiteModerna — Financial Overview, Stock Price, Market Cap
Moderna is a company. Founded in 2010. As of August 26, 2026, the company's market capitalization is $63021520380 with a current stock price of $158.83.